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Skin and chronic wound infections caused by various pathogenic bacteria are an
increasing and urgent health problem worldwide. In the present investigation ethyl
acetate extract of an Achromobacter sp. associated with a Rhabditis entomopathogenic
nematode (EPN), displayed promising antibacterial property and was further purified
by silica gel column chromatography to get three different cyclic dipeptides (CDPs).
Based on the spectral data and Marfey’s analyses, the CDPs were identified as
cyclo(D-Leu-D-Arg) (1), cyclo(L-Trp-L-Arg) (2), and cyclo(D-Trp-D-Arg) (3), respectively.
Three CDPs were active against all the 10 wound associated bacteria tested. The
significant antibacterial activity was recorded by CDP 3, and highest activity of 0.5µg/ml
was recorded against Staphylococcus aureus and Pseudomonas aeruginosa. The
synergistic antibacterial activities of CDPs and ampicillin were assessed using the
checkerboard microdilution method. The results of the current study recorded that
the combined effects of CDPs and ampicillin principally recorded synergistic activity.
Interestingly, the combination of CDPs and ampicillin also recorded enhanced inhibition
of biofilm formation by bacteria. Moreover, CDPs significantly stimulate the production
of IL-10 and IL-4 (anti-inflammatory cytokines) by human peripheral blood mononuclear
cells. CDPs do not make any significant effect on the production of pro-inflammatory
cytokines like TNF-α. The three CDPs have been studied for their effect on intracellular
S. aureus in murine macrophages (J774) using 24 h exposure to 0.5X, 1X, and 2X MIC
concentrations. Significant decrease in intracellular S. aureus burden was recorded by
CDPs. CDPs also recorded no cytotoxicity toward FS normal fibroblast, VERO, and L231
normal lung epithelial cell lines. Antimicrobial activity of the arginine containing CDPs
against the wound associated bacteria is reported here for the first. Moreover, this is also
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the first report on the production of CDPs by Achromobacter sp. Finally, we conclude that
the Achromobacter sp. is an incredibly promising source of natural bioactive secondary
metabolites especially against wound pathogenic bacteria that may receive significant
benefit in the field of human medicine in near future as topical agents.
Keywords: Achromobacter sp., arginine, diketopiperazines, antibacterial, wound
Introduction
Hospital-acquired infections remain one of the important causes
of morbidity, extended hospital stay and death for many
patients worldwide (Sulaiman and Zayed, 2014). The wound
and burn represent a susceptible site for many opportunistic
microorganisms of endogenous and exogenous origin (Sulaiman
and Zayed, 2014). Chronic wounds and burns are one
of the worldwide health problems, independent of various
socioeconomic and geographic boundaries (Percival et al., 2011).
In the United States alone, chronic wounds/burns involve more
than 5.5 million patients per year at a cost in excess of 20 billion
dollars annually. The occurrence and prevalence of chronic
wounds/burns are set to increase among patients irrespective
of various disease pathophysiology and age (Percival et al.,
2011). The pathogenic microorganisms that are normally isolated
from various chronic wounds have included Staphylococcus
aureus,Corynebacterium spp., Pseudomonas aeruginosa, Candida
albicans, etc. (Moore et al., 2010; Percival et al., 2011). But, S.
aureus is the leading causative organism of many serious acute
and chronic wound/burns infections in human beings and is
one of the major pathogenic microorganisms associated with
wound/burn (Dowd et al., 2008; Fazli et al., 2009; Harbarth
et al., 2011; Müller et al., 2013). In S. aureus strains, methicillin-
resistant S. aureus (MRSA) have become increasingly common in
wounds/burns, and the wide spread of MRSA signifies a solemn
health threat to humans and animals around the globe (Müller
et al., 2013). However, long-lasting wounds are colonized by
many adverse polymicrobial microflora that can increase the risk
of an infection development in patients.
The antimicrobial resistance is a growing concern for public
health worldwide (Levy and Marshall, 2004). The drug resistant
microorganisms of most concerns to wound/burn are often
called “superbugs” and these drug resistant microorganisms
have the capability to resist various clinical used antibiotics
currently (Percival et al., 2011). Antibiotic-resistant bacteria
in wounds/burns include MRSA, glycopeptide-resistant
enterococci, and multidrug-resistant strains of Acinetobacter
baumannii and P. aeruginosa, which all present a very serious
management risk. Subsequently, when infections happen in
wounds/burns and the colonizing microorganism frequently
grow in biofilms, which are highly resistant to many clinically
antibiotics and our ability to cure these infections is very much
limited (Kennedy et al., 2010; Percival et al., 2011; Vojtová et al.,
2011). In these circumstances, sepsis in burn patients becomes a
major concern (Kennedy et al., 2010). Wound/burn associated
infections are one of the most common surgical complications in
patients that may lead to high levels of morbidity and mortality.
Surgical and burn infections are reported as one of the most
common form of hospital-acquired infections and reported from
both the UK and the USA to occur in more than 40% of patients
(Valencia et al., 2004; Percival et al., 2011). Research on hospital
infections in India reveals several concerning trends like post-
operative wound infection with multidrug-resistant bacteria like
MRSA, vancomycin-resistant S. aureus (VRSA), carbapenem-
resistant P. aeruginosa, etc. (Setty et al., 2014). In India, more
than 80% of S. aureus isolated from hospital-acquired infections
were resistant to methicillin and vancomycin (Rao et al., 2013).
Moreover, the incidence of MRSA varies from more than 25% in
western part of India to 50% in South India [Indian Network for
Surveillance of Antimicrobial Resistance (INSAR) Group, 2013].
Industrial development of novel groups of antimicrobial agents
has reduced over last 15–20 years, and few pharma companies
remain active to find out novel drugs with antibiotic property
from natural sources (Müller et al., 2013). So, there is a very
urgent need for novel methods or antibiotics to treating various
multidrug-resistant bacterial infections are very much essential.
To combat multi-drug resistant wound pathogens, the
combination of two or more antibiotics is widely practiced.
Moreover, combination of antibiotics can result in synergistic
effect to offer improved antimicrobial activity and this also led to
the reduction of quantity of individual antibiotic used, which in
turn diminish the risk of various unwanted side effects and other
treatment costs (Lee et al., 2007; Leibovici et al., 2010; Müller
et al., 2013). Moreover, antibiotics in synergistic combination
with different mechanism of action diminish the possible risk
of drug-resistance arising during chemotherapy (Müller et al.,
2013). This is predominantly crucial for patients with chronic
wounds/burns where drug therapy is often continued for a very
long period.
EPN carrying symbiotic bacteria (mainly Photorhabdus or
Xenorhabdus, respectively) symbolize one of the best eco-friendly
strategies to control many insect pests (Lang et al., 2011; Zhu
et al., 2011; Salvadori et al., 2012). In natural condition, the
active infective juveniles (IJ) of these EPN (Heterorhabditis
or Steinernema genera) actively searching for suitable host in
the soil, enter through the insect’s natural openings like anus,
mouth etc., reaching hemocoel where they release the symbiotic
bacteria (Salvadori et al., 2012). In hemocoel bacteria multiply
vigorously and secrete a large number of chemicals, including
various toxin complexes, hydrolytic enzymes, hemolysins, and
antimicrobial compounds, which kill the insect host usually
within 24–48 h (Ffrench-Constant et al., 2007; Eleftherianos
et al., 2010; Salvadori et al., 2012). Due to the presence of
diverse antimicrobial compounds, the cadaver remains without
putrification for so many days thus providing required nutrients
for the nematodes development and reproduction (Salvadori
et al., 2012).
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During our research on EPN, a novel EPN belonging to
the genus Rhabditis and subgenus Oscheius was isolated from
soil samples collected from cassava field, Kollam, Kerala, India
(Mohandas et al., 2007). The nematodes can be cultured in
Galleria mellonella larvae (laboratory reared) and preserved alive
for several years in fresh water. A specific symbiotic bacterium
were found to be associated with the Rhabditis nematode
(Mohandas et al., 2007) and can be isolated from the hemolymph
of EPN infested G. mellonella larvae. Based on molecular
characteristics, nematode resembles Rhabditis (Oscheius) (Deepa
et al., 2010). The bacterial cell free culture filtrate was
found to inhibit numerous human and animal pathogenic
microorganisms, signifying the presence of many bioactive
molecules with antimicrobial property (Mohandas et al., 2007).
In this study, we reported the taxonomic study of the symbiotic
bacteria, purification, and structure elucidation of three arginine
based cyclic dipeptides, its synergistic antimicrobial activity
with special reference to major clinically relevant wound
bacteria. The current study reports the antimicrobial activity
of arginine based cyclic dipeptides for the first time from
Achromobacter sp.
Materials and Methods
Chemicals and Media
The solvents used for extraction, silica gel column
chromatography andHigh Performance Liquid Chromatography
(HPLC) were procured from Merck India Limited,
Mumbai, India. Silica gel (230–400 mesh) used for column
chromatography and precoated silica gel 60 GF254 plates used for
Thin Layer Chromatography (TLC) were from Merck Limited,
Germany. Media used for microbiological assays were procured
from Hi-Media Laboratories Limited, Mumbai, India. All other
chemicals and reagents used in the present investigation were of
the highest purity. The standard antimicrobial drug ampicillin
was procured from Sigma-Aldrich (USA). The Chemsketch Ultra
software (Toronto, Canada) was used for drawing the chemical
structure of isolated compounds.
Wound Associated Microbial Targets
The major wound associated bacteria used in the present
study are Gram-positive: Bacillus subtilis (MTCC 2756), S.
aureus (MTCC 902), Staphylococcus epidermidis (MTCC
435), Streptococcus faecalis (MTCC 5383); Gram-negative:
Escherichia coli (MTCC 2622), Klebsiella pneumoniae (MTCC
109), Proteus mirabilis (MTCC 425), P. aeruginosa (MTCC
2642), Salmonella typhi (MTCC 3216), Proteus vulgaris (MTCC
742), Enterococcus faecium (MTCC 439). The test pathogens
were obtained from Microbial Type Culture Collection Centre
(MTCC), Institute of Microbial Technology (IMTECH),
Chandigarh, India and maintained on nutrient agar (NA) slants
at 4◦C.
Bacterial Isolation
The beneficial bacterium was isolated from the haemolymph
of G. mellonella infected with infective juveniles of Rhabditis
sp. Dead G. mellonella larvae were surface sterilized in 70%
alcohol for 10–15min, flamed for few seconds and allowed to
dry in a laminar airflow chamber for 15–20min. Then larvae
were opened with sterile needles and scissors, without damaging
the gut portion, and a loop full of oozing haemolymph was
streaked onto nutrient agar plates. After 48 h incubation at 30◦C,
single colonies on the NA plates were selected and aseptically
transferred to fresh NA slants.
Molecular Characterization of Symbiotic
Bacterium
DNA Extraction and 16S rDNA Sequencing
For the extraction of genomic DNA, isolated bacteria colonies
were collected from theNA plates in 500µl sterile double distilled
water in 1.5ml microtubes. Cells were disrupted by heating at
100◦C for 10min and then centrifuged at 10,000 g for 2min
and the supernatants were deproteinized by adding 200µl of
chloroform: isoamylic acid (24:1 v/v) followed by centrifugation
for 10min at 10,000 g. The aqueous portion containing DNA
were transferred to fresh 1.5ml microtubes and stored at −20◦C
for further studies. Previously reported primers were used for
amplify the 16S rDNA region (Kim et al., 2009; Salvadori et al.,
2012).
PCR amplification was done according to the method of
Saiki et al. (1988), with some minor changes. The standard
50µl PCR mixtures contained 5× reaction buffer (10µl),
dNTP mixture (1µl, 2.5mM each), 5µM forward primer
(2µl), 5µM reverse primer (2µl), Taq polymerase (0.25µl;
5 U/µl), template DNA (3µl), and sterile distilled water
(31.75µl). The controls tubes contained all components used
for PCR except template DNA. After that, the PCR mixtures
were incubated in a PCR thermal cycler for a series of 35-
cycle amplification. After initial denaturation (94◦C for 3min),
each cycle included denaturation at 94◦C for 45 s, annealing
at 62◦C for 45 s, and extension at 72◦C for 2min. After
that the final extension was carried out at 72◦C for 7min.
The amplified products were separated on agarose gel (1%)
containing ethidium bromide (0.5µg/ml) and were viewed
under UV light using Gel documentation system (Bio-Rad).
Final PCR products were further purified with Illustra™ GFX™
PCR DNA and Gel Band Purification Kit (GE Healthcare,
UK) following the manufacturer’s instructions. DNA Sequencing
was carried out at the DNA fingerprinting unit of Rajiv
Gandhi Center for Biotechnology (RGCB), Trivandrum, Kerala,
India using a PCR thermal cycler (GeneAmp PCR System
9700, Applied Biosystems) using the BigDye Terminator v3.1
Cycle sequencing Kit (Applied Biosystems, USA) following
manufacturers protocol. The genes were then finally aligned to
the corresponding sequences available in the NCBI nucleotide
database by nBLAST.
Phylogenetic Analyses of the Sequences
Mega (Molecular Evolutionary Genetic Analysis) software
version 5.0 (Tamura et al., 2007) was used to analyze the
evolutionary distances following Kimura-2 parameter (Kimura,
1980). The phylogenetic tree was created by the neighbor-joining
method, and bootstrap analysis was used to assess the tree
topology by performing at least 1000 re-samplings (Saitou and
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Nei, 1987). The taxonomic status of the present strain was
established based on 16S rDNA homology.
Fermentation and Extraction of Secondary
Metabolites
The bacterial fermentation for antibacterial secondary metabolite
production was carried out using a modified Tryptic soya broth
(TSB) (original TSBmedia supplemented with 1% beef extract) as
reported earlier (Kumar et al., 2014a). A total of 25 L of bacterial
cell-free culture filtrate were produced and neutralized with the
concentrated hydrochloric acid and extracted with ethyl acetate
(equal volume) thrice, dried over anhydrous sodium sulfate,
and concentrated at 42◦C using a Buchi rotary flash evaporator
(Kumar et al., 2014a).
Fractionation of the Crude Ethyl Acetate Extract
The fractionation of ethyl acetate extract was done according
to our previously reported method with minor modification in
the combination of solvent system (Kumar et al., 2014a). Heat
activated silica gel (230–400 mesh) was packed into a glass
column (600 × 30mm) using n-hexane and eluted sequentially
with 500ml of n-hexane (100%), 500ml of linear gradient hexane:
dichloromethane (v/v, 90:10–10:90), 500ml of dichloromethane
(100%), 500ml of linear gradient dichloromethane: ethyl acetate
(v/v, 95:5–5:95), 500ml of ethyl acetate (100%), and finally with
500ml of acetone (100%). Five fractions (100ml each) were
collected from each solvent combination and concentrated by
using the Buchi rotary evaporator at 40◦C (Kumar et al., 2014a).
Thin-layer Chromatography (TLC)
TLC profile of the compounds was carried out on silica gel plates
(Merck 60, F254) using ethyl acetate and acetone (90:10 v/v). The
compounds were located by exposing the TLC plate to iodine
fumes.
Reverse Phase-High Pressure Liquid
Chromatography (RP-HPLC)
The final purity of the compounds were analyzed by an LC-
10AT liquid chromatography (Shimadzu, Singapore) equipped
with a C-18 column (5µm, 4.6 × 250mm). Samples of 20µl
were injected to a column and eluted using the following gradient
program: solvent A (water), solvent B (MeCN); 0min 50% B,
15min 75% B, 25min 100% B; UV detection at 210 nm with a
flow rate of 1ml/min.
Structure Elucidation of Pure Compounds
1H NMR and 13C NMR spectra were acquired using a Bruker
DRX 500 NMR spectrometer (Bruker, Rheinstetten, Germany)
at 20◦C and Chemical shifts are reported relative to the
corresponding reference solvent (DMSO-d6: 1H δ 2.50 and 13C δ
39.52). Thermo Scientific Exactive Mass Spectrometer (Thermo
Fisher Scientific, Bremen, Germany) with an electrospray
ionization mode was used to record HRESIMS. Optical rotations
were measured on a Rudolph Research Autopol III digital
polarimetric apparatus (Hackettstown, NJ, USA). Melting points
(m.p.) were determined on a Mettler Toledo DSC 822e apparatus
(Mettler-Toledo, Schwerzenbach, Switzerland).
Marfey’s Analysis (Acid Hydrolysis) of Pure
Compounds
Compounds (1.5mg) each was dissolved in 0.1ml 6 mol/L HCl
and hydrolyzed at 110◦C for 20 h. After drying, the hydrolysate
was dissolved in distilled H2O and was then placed in a 1ml
reaction tube and treated with a 2% solution of FDAA (200µl)
in acetone followed by 1.0mol/L NaHCO3 (40µl). This reaction
mixture was heated at 49◦C for 1 h, cooled to room temperature,
and then acidified with 2.0mol/L HCl (20µl). In a similar way,
standard D- and L-amino acids were derivatized separately. RP-
HPLC of the hydrolysate was done in a Shimadzu LC-20AD, C-18
column; (5µm, 4.6 × 250mm) with a flow rate of 1.0ml/min
at 30◦C using an eluent system consisting of 0.2% aqueous TFA
(eluent A) and MeCN (eluent B). A linear gradient from 25%
eluent B (0min) to 60% eluent B (40min) and to 100% eluent
B (45min) was applied. Absorbance was recorded at 340 nm
(Marfey, 1984).
Antibacterial Activity of Compounds against
Wound Pathogens
Determination of Minimal Inhibitory Concentration
(MIC) and Minimal Bactericidal Concentration (MBC)
The MIC value of the compounds against the test wound
associated pathogens was determined by microdilution method
as suggested by Clinical and Laboratory Standards Institute
(CLSI, 2012). The compounds were transferred to a 96 well
microplate in order to get twofold serial dilutions of the
test compounds and antibiotics. After that, 20µl inoculum
containing 5 × 105 CFU/ml of corresponding test bacteria
was added to each well, and the microplates were incubated
at 37◦C for 24 h. Wells without test pathogens were used as
sterility control, and the positive controls encompassed of test
bacteria without the test compounds. After incubation, bacterial
growth was indicated by the presence of turbidity, which was
confirmed by adding 20µl of resazurin (Sigma-Aldrich, USA)
and incubated for 1 h at 37◦C. TheMIC was defined as the lowest
concentration of the test compound/antibiotics that was able to
inhibit the bacterial growth. Ampicillin was used as a standard
antimicrobial agent (Silva et al., 2013).
The serial dilution method was also used to establish the MBC
values. For this, 20µl of the microbial culture were withdrawn
from wells with concentrations of compounds equal to, or higher
than, the MIC, serially diluted, plated on nutrient agar plates,
and incubated at 37◦C for 24 h and colonies were counted after
incubation (Silva et al., 2013). TheMBCwas defined as the lowest
concentration of compound/antibiotics at which the entire test
bacteria have been killed (99.99% reduction). The experiments
were performed for three times.
Disc Diffusion Test to Check Antibacterial
Susceptibility
Antibacterial susceptibility testing of the compounds was
performed by standard disk diffusion assay according to CLSI
protocol (CLSI, 2009). The inoculum was prepared by picking
the test bacteria from plates with a sterile inoculating loop and
suspended in sterile normal saline (0.85%). The density of the
suspension to be inoculated was determined by comparison
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with McFarland 0.5 standard. After that, the test bacteria was
swabbed uniformly over the Mueller-Hinton agar (MHA) plates,
and filter paper disc (6mm, Hi-media) incorporated with MIC
concentration of the test compounds are placed in the agar
medium. After that, the plates were incubated for 18 h at 37◦C
and the diameters of zones of inhibition around the discs were
measured in millimeter (mm). The experiments were repeated
for three times.
Synergistic Activity of the Test Compounds and
Antimicrobial Drug against Wound Pathogens
The synergistic antimicrobial activity of the test compounds
and antimicrobial drug (ampicillin) was determined by a
checkerboard assay according to the modified method of Silva
et al. (2013), with the CLSI microdilution method. The test
compounds and ampicillin were combined in concentrations
lower than their individual MIC values by serial dilution in 96
well microplates. The bacterial test inoculum (20µl) containing
5×105 CFU/ml was added to each well, and the microplates were
incubated for 24 h at 37◦C. The bacterial growth was confirmed
by adding resazurin (20µl) and incubated for 1 h at 37◦C (Lee
et al., 2012). Triplicate set of experiments were performed.
To assess the interaction of combinations of test compounds
and ampicillin, the results obtained were further analyzed
using the fractional inhibitory concentration (FIC) index.
The interaction of two compounds was regulated as synergy,
indifferent or antagonistic on the basis of the FIC index values.
The FIC-values were calculated as follows:
FIC of compound A (test compounds) (FICA) = (MIC of
compound A in combination)/(MIC of compound A alone)
FIC of compound B (ampicillin) (FICB)= (MIC of compound
B in combination)/(MIC of compound B alone)
The sum of fractional inhibitory concentration indices (FICI)
of two compounds (A and B) in the combination was
calculated as follows:
FICA + FICB = FICI.
The interaction between compounds and antibiotics was
considered to be synergistic when FICI ≤0.5, indifferent at
0.5 < FICI < 4, and antagonistic when FICI ≥4 (Cordeiro
et al., 2003).
The fractional bactericidal concentration (FBC) is calculated in
the same way described above by substituting the MIC values
with the MBC values.
Inhibition of Bacterial Biofilm Formation by the
Combination of Test Compounds and Ampicillin
The test compounds and ampicillin alone and in combinations
were tested for their potential to prevent biofilm formation in
the wound associated bacteria. The test bacteria were added
to the growth medium at the time of inoculation, and the
bacterial cells were allowed to form the biofilm. An aliquot of
twofold serial dilutions (100µl) was prepared in the 96-well
microtitre plate containing TSBGlc as growth medium, with the
MIC concentrations of test compounds and ampicillin alone
and in combination. The test bacterial suspensions (20µl; 5 ×
105 CFU/ml) were then added to the plate. TSBGlc containing
0.2% DMSO was employed as a negative control. Non-treated
control TSBGlc without the test compounds and ampicillin and
the medium with each concentration of the test compounds
was used as the blank control (Chusri et al., 2012). After
incubation for 24 h at 37◦C, the impact of the combinations on
the growth of test bacteria was evaluated using the microplate
(ELISA) reader (Bio-rad, USA) at an optical density of 600 nm.
The biofilm formation of test bacteria in the presence of the
combination of test compounds and ampicillin was recorded
using the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium-bromide) assay.
MTT (Sigma-Aldrich, USA) reduction assay according to the
method previously reported by Tang et al. (2011) was used to
quantify the biofilm forming capability of the test pathogens.
An aliquot (200µl) of MTT solution (0.2mg/ml) was added to
each of the prewashed wells, and the plate was again incubated at
37◦C for 3 h in the dark. After 3 h, MTT solution was replaced
by adding DMSO (200µl). Bacterial pathogens with an active
electron transport systemwill easily reduce the tetrazolium salt to
a water-insoluble purple formazan product (Chusri et al., 2012).
The color intensity was determined by an ELISA microplate
reader (Bio-rad, USA) at 482 nm. The absorbance values for the
negative control were then subtracted from the tested wells to
eliminate false results due to background interference. Triplicate
set of experiments were performed (Chusri et al., 2012).
Immunomodulatory Property of Test Compounds
Cytokine Release Measurement
Peripheral blood mononuclear (PBM) cells were isolated from
the heparinized venous blood of healthy donors by density
gradient centrifugation using Histopaque 1077. The PBM cells
were then washed three times with RPMI 1640 medium and
finally resuspended in the RPMI 1640 containing 10% fetal
bovine serum (FBS), 2mM L-glutamine, penicillin G (100
IU/ml), and streptomycin (100µg/ml). Trypan blue staining was
used to determine the cell number and viability. Freshly isolated
PBM cells were grown in 96 well plates at an initial density of
2 × 105 cells/well and incubated with test compounds (0.1, 1,
and 10µg/ml). The control well contains medium alone. The
plates marked as Con A in Figure 5 consisted of cells treated in
the similar way but in the presence of standard concanavalin A
(2.5µg/ml). Cells were incubated for 36 h at 37◦C in a humidified
atmosphere of 5% CO2–95% air. After incubation cells were
centrifuged, supernatants collected and kept at−20◦C for further
analysis (Mechkarska et al., 2013).
Cytokine concentrations in the supernatants (diluted 1:4)
were measured by ELISA reader (Bio-rad, USA) by OptEIA
assay kits from BD Biosciences (San Diego, USA) according
to manufacturer’s protocols: tumor necrosis factor-α (TNF-α),
IL-4, and IL-10. Triplicate set of experiments were performed
(Mechkarska et al., 2013).
Effect of Test Compounds on Murine Macrophage
J774 Cells Treated with S. aureus
To check the effect of test compounds onmurinemacrophage cell
line (J774), the murine macrophage was cultured in RPMI 1640
medium supplemented with L-glutamine and FBS. For bacterial
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(S. aureus) infection studies, J774 cells were transferred to 12 well
tissue culture plate in 1ml volumes at a density of 2× 105 in the
presence of 10% FBS. After overnight incubation, the medium
was replaced with fresh medium containing 1% FBS to arrest
macrophage cell division while maintaining cell viability. After
24 h, the macrophage monolayer was counted with an ocular
micrometer for the total number of cells per well to determine
the infection ratio. Phagocytosis was started at a S. aureus-
macrophage ratio of 4:1, and after removal of unphagocytosed
and adherent S. aureus cells, the inoculum was typically 0.5–
2 × 106 bacteria permg of cell protein, as for J774 macrophages.
The cells were infected for 4 h and after that, non-phagocytosed
S. aureus cells were washed from the monolayers, and fresh
medium was added. 0.5X, 1X, and 2X MIC concentrations
of test compounds were added and incubated for 24 h. After
incubation, the macrophages were lysed with sodium dodecyl
sulfate (SDS), treated with DNAase, diluted and plated onto NA
plates to determine the S. aureus cell number or colony forming
units (CFU). The experiment was repeated thrice to confirm the
observations. A cytotoxicity control plate assay (MTT) was also
conducted in parallel using uninfected macrophages to confirm
that concentrations utilized for testing were not toxic to the
macrophages (Papadopoulou et al., 2014).
Cytotoxicity of Pure Compounds
The MTT assay was used to check whether the isolated
compounds are cytotoxic to the normal cells or not. FS normal
fibroblast, VERO (African green monkey kidney), and L231
normal lung epithelial cell lines were used for the present
study. Briefly, normal cells (5 × 103 per well) were seeded
in 0.2ml of the medium (DMEM with 10% PBS) on 96 well
plates, treated with test compounds (5–100µg/ml) for 72 h.
After incubation cytotoxicity was measured by removing the
compounds containing media from the well and 25µl of MTT
solution (5mg/ml in PBS) and 75µl of complete medium were
added to wells (treated and control) and incubated for 2 h. After
incubation, MTT lysis buffer was added to the wells (0.1ml/well)
and again incubated for another 4 h at 37◦C. After that, the OD
at 570 nm was measured using an ELISA plate reader (Bio-Rad,
USA). The relative cell viability (%) was calculated (A 570 of
treated well)/(A 570 of untreated well) × 100. Triplicate set of
experiments were performed (Kumar et al., 2014b).
Statistical Analysis
All the statistical analyses were performed with SPSS (Version
17.0; SPSS, Inc., Chicago, IL, USA). In MIC, MBC, and
FICI determinations, when the results were different in both
experiments, we made another test for the final result. One-Way
ANOVA-Duncan’s multiple range test was used and the statistical
significance was defined as p < 0.05.
Results
Molecular Identification of Bacterium
The bacterium (Achromobacter sp.) was identified based on 16S
rDNA gene sequencing. PCR amplification yielded ∼1500 bp
amplicon. BLAST analysis recorded 99% similarity to
Achromobacter sp. sequence available in the NCBI Genbank
database and thus, the test bacterium was identified as
Achromobacter sp. The 16S rDNA gene sequence data have
been deposited in the NCBI nucleotide database (Ac. No.
HQ200410). The phylogenetic tree clearly portrayed the
relationships of the isolates used in the analysis. Thus, the
Achromobacter sp. was successfully grouped along with other
Achromobacter sp. isolates obtained from the NCBI GenBank
database confirming the complete authenticity of our strain
(Figure 1). This Achromobacter sp. was presently deposited in
culture collection center of IMTECH (Institute of Microbial
Technology, Chandigarh, India).
Isolation, Purification, and Characterization of
Bioactive Compounds
The crude ethyl acetate extract recorded promising antibacterial
activity against S. aureus (indicator microorganism). Column
FIGURE 1 | Phylogenic relationships of Achromobacter sp. strain isolated from Rhabditis (Oscheius) sp. and known bacterial relatives based on 16S
rDNA gene sequences (neighbor-joining method).
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chromatographic purification of ethyl acetate extract yielded
three compounds. The eluted solvent system in column
chromatography and yield of each compound were revealed
in Table 1. The three compounds were further purified by
crystallization using hexane and benzene to yield white crystals.
Antibacterial activity of these crystals was again confirmed by
testing against S. aureus. TLC profile of these purified crystal
compounds recorded single spots, and RF-value is presented in
Table 1. In HPLC analysis, the compounds were eluted as single
peaks, which confirm its purity (Figure 2). The purity of the
compounds recorded more than 98%, according to the peak area
from the chromatogram.
Identification of Cyclic Dipeptides as
Antimicrobial Compounds
The three crystal compounds were subjected to various
spectroscopic analyses for elucidating the chemical structure, i.e.,
UV, HR-MS, and NMR (1H and 13C NMR). Based on spectral
data the compounds were identified as three different cyclic
dipeptides (CDPs) or diketopiperazines. The CDPs identified are
cyclo(D-Leu-D-Arg) (1), cyclo(L-Trp-L-Arg) (2), and cyclo(D-
Trp-D-Arg) (3), respectively (Figure 3).
CDP 1: Cyclo(D-Leu-D-Arg) (1-{3-[(2R,5R)-5-(2-
methylpropyl)-3,6-dioxopiperazin-2-yl]propyl}guanidine):
1H NMR (DMSO-d6, 500 MHz) δ 7.91 (1H, br s, Arg-NH), δ
4.13(1H, dd, J = 8.2, 8.1Hz, Arg-H2), δ 4.04 (1H, dd, J = 6.8,
5.7Hz, Leu-H2), δ 3.47 (1H, m, Arg-H5), δ 3.26 (1H, m, Arg-H5),
δ 2.18 (1H, m, Arg-H3), δ 1.99 (1H, m, Arg-H3), δ 1.94 (2H,
m, Leu-H4), δ 1.75 (2H, m, Arg-H4), δ 1.75 (1H, m, Leu-H3),
δ 1.32 (1H, m, Leu-H3), δ 0.83 (3H, d, J = 7.0Hz, Leu-H5),
δ 0.81 (3H, d, J = 7.0Hz, Leu-H50); 13C NMR (DMSO-d6,
125 MHz) 170.1, 167.4, 58.7, 53.9, 45.9, 38.1, 28.3, 24.1, 24.0,
23.1, and 22.9. The molecular formula of this compound was
determined to be C12H24O2N5 by HR-ESI-MS at m/z 270.22351
[M+H].
CDP 2: Cyclo(L-Trp-L-Arg) (1-{3-[(2S,5S)-5-(1H-indol-
3-ylmethyl)-3,6-dioxopiperazin-2-yl]propyl}guanidine): 1H
NMR (DMSO-d6, 500MHz) 10.77d (d, J = 2.3), 8.17 (d,
J = 2.4), 8.11 (d, J = 2.3), 7.69 (dd, J = 8.0, 1.0), 7.41 (d,
J = 8.1), 7.28 d (t, J = 5.7), 7.15 (ddd, J = 8.0, 7.0, 1.1), 7.12
(s), 7.01 (ddd, J = 8.0, 7.0, 1.0), 4.37 (ddd, J = 4.8, 3.7, 1.3),
3.74 (ddd, J = 7.7, 5.2, 1.5), 3.51 (dd, J = 14.8, 3.6), 3.19 (dd,
J = 14.7, 4.6), 2.72 (d, J = 7.0, 2.0), 0.81 (m), 0.79 (m), 0.54
(m). 13C NMR (DMSO-d6, 125 MHz) 169.81, 169.28, 158.54,
137.85, 129.41, 126.17, 122.44, 120.35, 120.29, 112.32, 109.60,
57.21, 55.24, 41.68, 32.16, 30.52, and 24.59. The molecular
formula of this compound was determined to be C17H23O2N6
by HR-ESI-MS at m/z 343.39558 [M+H].
CDP 3: Cyclo(D-Trp-D-Arg) (1-{3-[(2R,5R)-5-(1H-indol-
3-ylmethyl)-3,6-dioxopiperazin-2-yl]propyl}guanidine): 1H
NMR (DMSO-d6, 500 MHz) 10.91d (d, J = 2.3), 8.21 (d,
J = 2.4), 8.24 (d, J = 2.3), 7.77 (dd, J = 8.0, 1.0), 7.43 (d,
J = 8.1), 7.34 d (t, J = 5.7), 7.21 (ddd, J = 8.0, 7.0, 1.1), 7.22
(s), 7.01 (ddd, J = 8.0, 7.0, 1.0), 4.43 (ddd, J = 4.8, 3.7, 1.3),
FIGURE 2 | HPLC profile of CDPs on a reversed-phase C18 HPLC
column. Cyclo(D-Leu-D-Arg) (A), Cyclo(L-Trp-L-Arg) (B), and
Cyclo(D-Trp-D-Arg) (C).
TABLE 1 | Information regarding the isolated compounds.
S.no. Compounds Column solvent Yield (mg) Melting point (◦C) Optical rotation (c, 0.02, MeOH)
1 Cyclo(D-Leu-D-Arg) 30% DCM in hexane 19 202.51−205.55 [a]D − 118
2 Cyclo(L-Trp-L-Arg) 75% DCM in hexane 16 265.1−267.34 [a]D + 145
3 Cyclo(D-Trp-D-Arg) 15% ethyl acetate in DCM 21 262.23−265.58 [a]D − 167
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3.88 (ddd, J = 7.7, 5.2, 1.5), 3.61 (dd, J = 14.8, 3.6), 3.33 (dd,
J = 14.7, 4.6), 2.77 (d, J = 7.0, 2.0), 0.88 (m), 0.79 (m), 0.61 (m).
13C NMR (DMSO-d6, 125 MHz) 170.11, 170.01, 158.79, 138.22,
130.28, 127.17, 123.14, 121.38, 121.32, 113.28, 109.66, 59.01,
54.67, 41.99, 32.86, 31.48, and 25.5. Themolecular formula of this
compound was determined to be C17H23O2N6 by HR-ESI-MS at
m/z 343.37431 [M+H].
Absolute Configuration Determination of Cyclic
Dipeptides
The advanced Marfey’s analysis was effectively employed for
determining the absolute configuration of CDPs. Regarding the
absolute configuration of compounds, the CDP 1 and 3 contain
D-amino acids, whereas CDP 2 contains L-amino acids (Data not
shown). The three derivatives obtained by the acid hydrolysis of
FIGURE 3 | Chemical structure of cyclic dipeptides. Cyclo(D-Leu-D-Arg)
(1), Cyclo(L-Trp-L-Arg) (2), and Cyclo(D-Trp-D-Arg) (3).
the CDPs were compared with the HPLC retention times of the
derivatized standard D and L-amino acids.
Antibacterial Activity of Cyclic Dipeptides
The pure CDPs were tested for antibacterial activity against 10
wound associated bacterial pathogens using CLSI protocol. MIC
and MBC values of CDPs were recorded and are presented in
Table 2. The test pathogen that exhibited the highest sensitivity
toward CDP 1 was B. subtilis. CDP 2 was active against all the
test bacteria only at higher concentration and best activity of
this compound was recorded against S. epidermidis (32µg/ml),
followed by S. aureus (64µg/ml). Interestingly, CDP 3 recorded
good activity against all test pathogens in impressively low
concentration, and best activity was recorded against S. aureus
and P. aeruginosa (0.5µg/ml). The activity of the test compounds
was better than the ampicillin, standard antimicrobial drug. The
disc diffusion assay of the CDPs against test bacteria was shown
in Table 3.
TABLE 3 | Antimicrobial activity of cyclic dipeptides against wound
associated bacteria.
Test bacteria Inhibition zone (dia. in mm)
CDP 1 CDP 2 CDP 3 Ampicillin
B. subtilis 18± 1 17± 0 24±0 26± 0
S. aureus 20± 1 18± 0.57 35±0.57 28± 1
S. epidermidis 21± 1.52 15± 0 27±1.15 30± 1.15
S. faecalis 17± 1 15± 0.57 30±1.15 29± 0
E. faecium 23 12± 0.57 31±1.15 26± 1
P. aeruginosa 21 11± 0 34±1 25± 0.57
P. vulgaris 20 13± 0.57 29±1.73 30± 0
P. mirabilis 16± 0 13± 0.57 30±0 24± 1.52
K. pneumonia 18± 1.2 10± 0 27 27± 0.57
S. typhi 21 9± 1.2 23±1 30± 1.52
Values represent mean of three replications.
TABLE 2 | MIC and MBC of cyclic dipeptides against wound associated bacterial pathogens.
Test bacteria MIC (µg/ml)
CDP 1 CDP 2 CDP 3 Ampicillin
MIC MBC MIC MBC MIC MBC MIC MBC
B. subtilis 8 16 125 125 4 8 8 16
S. aureus 16 32 64 64 0.5 0.5 4 4
S. epidermidis 16 16 32 64 8 16 4 8
S. faecalis 32 64 500 1000 4 8 8 16
E. faecium 16 32 250 250 2 4 2 4
P. aeruginosa 125 250 250 500 0.5 0.5 2 2
P. vulgaris 500 500 1000 1000 4 8 2 4
P. mirabilis 125 125 1000 2000 64 128 4 8
K. pneumonia 250 500 125 250 2 4 4 8
S. typhi 64 125 125 250 32 64 8 16
No of MIC up to 1000µg/ml.
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Cyclic Dipeptides Synergistically Enhance the
Activity of Ampicillin against Wound Pathogens
The combined activities of CDPs with ampicillin from the
in vitro checkerboard assay against wound associated bacteria
are shown in Table 4. FIC, FBC, FIC index, FBC index
and interpretations for the activities of CDPs, and ampicillin
against the test bacteria predominantly recorded the synergistic
interaction, i.e., significant enhancement in the bioactivity. But
CDP 1 with ampicillin against P. aeruginosa and CDP 2 with
ampicillin against K. pneumonia recorded additive. Antagonism
and indifference were not recorded for the combinations. When
CDP 3 was combined with ampicillin for the inhibition of P.
aeruginosa, an important synergistic effect (FIC = 0.09) was
observed and the MIC values of CDP 3 and ampicillin were
reduced to more than five times below their individual MIC
values, respectively (Table 4). From the checkerboard assay,
it is clearly evident that the CDPs enhance the activity of
ampicillin against wound bacterial pathogen tested and in most
combinations the MIC level has reduced many folds. This data
clearly indicated that the combination is more effective than the
individual compounds.
Combination of Cyclic Dipeptides and Ampicillin
Significantly Increases the Inhibition of Biofilms
Formation
The effects of the combination of CDPs and ampicillin on the
inhibition of wound associated bacterial biofilm formation were
shown in Figure 4. The combination of CDPs and ampicillin
recorded significant inhibition in the biofilm formation by the
bacterial pathogens when compared to the effect of individual
compounds. Significant inhibition in the biofilms was recorded
by CDP 3 in combination with ampicillin when compared to the
other CDPs.
Immunomodulatory Actions of Cyclic Dipeptides
The abilities of CDPs to modulate the production of cytokines
are shown in Figure 5. Incubation with the CDPs significantly
enhanced the production of cytokine IL-10 by unstimulated
cells and also boosted the production in cells stimulated with
concanavalin A (standard T cell mitogen activator) (Figure 5A).
Production of IL-4 by unstimulated cells was significantly
enhanced in the presence of 10µg/ml CDPs, but the compound
was without significant effect on concanavalin A-stimulated cells
(Figure 5B). Production of the pro-inflammatory cytokine TNF-
α was not affected by incubation with the CDPs in the presence
or absence of concanavalin A (Figure 5C).
Cyclic Dipeptides Recorded Significant Toxicity
toward the Intracellular S. aureus
Infected murine J774 cells were treated with 1X and 2X MIC
concentrations of CDPs. Significant decreases in bacterial loads
were consistently observed for the treatment of CDPs (Figure 6),
whereas none was observed with the solvent control (Figure 6).
However, CDP 3 treatments significantly reduced the number
of viable intracellular S. aureus at their respective 0.5X, 1X,
and 2X MIC concentrations in J774 macrophages. Interestingly,
cytotoxicity was not recorded for the uninfected macrophages by
CDPs (data not shown).
Cyclic Dipeptides Recorded No Cytotoxicity
toward Normal Cell Lines
Cytotoxicity activity of CDPs against three normal cell lines after
72 h of treatment was recorded by MTT assay and was presented
in Figure 7. When exposed to CDPs in the range, 5–100µg/ml,
CDPs recorded no cytotoxicity against FS, VERO, and L231 cell
lines (Figure 7).
Discussion
Cyclic dipeptides or CDPs (diketopiperazines or 2,5-
Diketopiperazines or 2,5-DKP) are the smallest cyclic
peptides known so far and are generally biosynthesized
from various amino acids by a large variety of organisms,
including microorganisms, sponges, mammals etc. (Sammes,
1975; de Carvalho and Abraham, 2012). The ability of various
microorganisms including bacteria and fungi to synthesize CDPs
is widespread and based on published reports more than 90%
of Gram-negative bacteria produce them (de Carvalho and
Abraham, 2012). CDPs have also been isolated from various
Gram-positive bacteria (Stierle et al., 1988; De Rosa et al., 2003),
fungi (Bugni and Ireland, 2004), and higher marine organisms
including sponges (Huang et al., 2010). Significant biological
activities of CDPs include anticancer, antiviral, antifungal,
antibacterial, antiprion, antihyperglycemic, and glycosidase
inhibitor agents etc. (de Carvalho and Abraham, 2012). Some
CDPs recorded affinities for calcium channels and opioid,
GABAergic, serotoninergic 5-HT1A and oxytocin receptors (de
Carvalho and Abraham, 2012). Numerous studies are focused
on important biological properties of CDPs connected to the
inhibition of plasminogen activator inhibitor-1 (Folkes et al.,
2001; Seko et al., 2002; de Carvalho and Abraham, 2012) and
modification of cardiovascular and blood-clotting functions
(McCleland et al., 2004; Cheng and Manwell, 2005). It is also
well reported that some CDPs can block the development of
physical dependence in mice (Walter et al., 1979; de Carvalho
and Abraham, 2012). Moreover, CDPs are able to trigger
quorum-sensing systems of bacteria via LuxR-mediation, and
even they are reported to influence cell to cell communication
in bacteria (Withers et al., 2001; Abraham, 2005; LaSarre and
Federle, 2013). In addition, they have been reported as part of
antibacterial nucleosides (Ichikawa and Matsuda, 2008).
CDPs are abound in nature and are often formed during
the processing of various food items, degradation products
of polypeptides, and beverages (Borthwick, 2012). They are
usually formed during the condensation of two α-amino acids.
According to Borthwick (2012) “CDPs occur in numerous
natural products, and this subunit is often found alone or
embedded in larger, more complex architectures in a variety
of natural products from microbes, plant, and mammals.”
CDPs have highly privileged structures that have the capability
to bind to various biological receptors and also have several
structural characteristics which make them attractive scaffolds
for drug discovery programmes against various diseases and
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TABLE 4 | Synergistic effects of the cyclic dipeptides with ampicillin against wound associated bacteria.
Test bacteria Agent MIC/MBC (µg/ml) FIC/FFC FICIb/FFCIc Outcome
Alone Combinationa
B. subtilis CDP 1 8/16 1/2 0.13/0.13 0.16/0.16 Synergistic/synergistic
Ampicillin 8/16 0.25/0.5 0.03/0.03
CDP 2 125/125 16/16 0.13/0.13 0.26/0.26 Synergistic/synergistic
Ampicillin 8/16 1/2 0.13/0.13
CDP 3 4/8 1/1 0.25/0.06 0.31/0.12 Synergistic/synergistic
Ampicillin 8/16 0.25/0.5 0.06/0.06
S. aureus CDP 1 16/32 2/4 0.13/0.13 0.26/0.26 Synergistic/synergistic
Ampicillin 4/4 0.5/0.5 0.13/0.13
CDP 2 64/64 8/16 0.13/0.25 0.38/0.5 Synergistic/synergistic
Ampicillin 4/4 1/1 0.25/0.25
CDP 3 0.5/0.5 0.03/0.06 0.06/0.12 0.18/0.37 Synergistic/synergistic
Ampicillin 4/4 0.5/1 0.12/0.25
S. epidermidis CDP 1 16/16 1/1 0.06/0.06 0.19/0.12 Synergistic/synergistic
Ampicillin 4/8 0.5/0.5 0.13/0.06
CDP 2 32/64 4/4 0.13/0.06 0.26/0.19 Synergistic/synergistic
Ampicillin 4/8 0.5/1 0.13/0.13
CDP 3 8/16 1/1 0.13/0.06 0.25/0.12 Synergistic/synergistic
Ampicillin 4/8 0.24/0.24 0.12/0.06
S. faecalis CDP 1 32/64 4/8 0.13/0.13 0.19/0.19 Synergistic/synergistic
Ampicillin 8/16 1/2 0.06/0.06
CDP 2 500/1000 32/32 0.06/0.06 0.09/0.12 Synergistic/synergistic
Ampicillin 8/16 4/8 0.03/0.06
CDP 3 4/8 1/1 0.13/0.06 0.15/0.08 Synergistic/synergistic
Ampicillin 8/16 0.12/0.25 0.02/0.02
E. faecium CDP 1 16/32 4/8 0.02/0.02 0.14/0.15 Synergistic/synergistic
Ampicillin 2/4 0.25/0.5 0.12/0.13
CDP 2 250/250 32/64 0.13/0.26 0.38/0.51 Synergistic/additive
Ampicillin 2/4 0.5/1 0.25/0.25
CDP 3 2/4 0.5/1 0.25/0.25 0.31/0.31 Synergistic/synergistic
Ampicillin 2/4 0.12/0.25 0.06/0.06
P. aeruginosa CDP 1 64/125 16/16 0.25/0.13 0.31/0.19 Synergistic/synergistic
Ampicillin 8/16 0.5/1 0.06/0.06
CDP 2 125/250 8/16 0.06/0.06 0.19/0.19 Synergistic/synergistic
Ampicillin 8/16 1/2 0.13/0.13
CDP 3 0.5/1 0.03/0.03 0.06/0.03 0.09/0.06 Synergistic/synergistic
Ampicillin 8/16 0.25/0.5 0.03/0.03
P. vulgaris CDP 1 500/500 64/125 0.13/0.25 0.38/0.5 Synergistic/synergistic
Ampicillin 2/4 0.5/1 0.25/0.25
CDP 2 1000/1000 125/125 0.13/0.13 0.38/0.38 Synergistic/synergistic
Ampicillin 2/4 0.5/1 0.25/0.25
CDP 3 4/8 0.24/0.5 0.06/0.06 0.07/0.07 Synergistic/synergistic
Ampicillin 2/4 0.03/0.06 0.01/0.01
P. mirabilis CDP 1 125/125 16/16 0.13/0.13 0.19/0.19 Synergistic/synergistic
Ampicillin 4/8 0.25/0.5 0.06/0.06
CDP 2 1000/2000 125/250 0.13/0.13 0.38/0.26 Synergistic/synergistic
Ampicillin 4/8 1/1 0.25/0.13
CDP 3 64/125 16/32 0.25/0.25 0.38/0.38 Synergistic/synergistic
Ampicillin 4/8 0.5/1 0.13/0.13
(Continued)
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TABLE 4 | Continued
Test bacteria Agent MIC/MBC (µg/ml) FIC/FFC FICIb/FFCIc Outcome
Alone Combinationa
K. pneumonia CDP 1 250/500 32/64 0.13/0.13 0.26/0.26 Synergistic/synergistic
Ampicillin 4/8 0.5/1 0.13/0.13
CDP 2 125/250 32/64 0.26/0.26 0.51/0.51 Additive/additive
Ampicillin 4/8 1/2 0.25/0.25
CDP 3 2/4 0.12/0.24 0.06/0.06 0.12/0.12 Synergistic/synergistic
Ampicillin 4/8 0.25/0.5 0.06/0.06
S. typhi CDP 1 125/250 32/64 0.26/0.26 0.51/0.51 Additive/additive
Ampicillin 2/2 0.5/0.5 0.25/0.25
CDP 2 250/500 32/32 0.12/0.06 0.37/0.31 Synergistic/synergistic
Ampicillin 2/2 0.5/0.5 0.25/0.25
CDP 3 32/64 4/8 0.12/0.12 0.18/0.18 Synergistic/synergistic
Ampicillin 2/2 0.12/0.12 0.06/0.06
aThe MIC and MBC of cyclic dipeptides with ampicillin.
bThe fractional inhibitory concentration index (FIC index).
cThe fractional fungicidal concentration index (FFC index).
disorders (Borthwick, 2012). Moreover, CDPs are highly stable
to proteolysis. CDPs are one of the crucial molecules in
drug discovery programmes because its rigid backbone, which
can mimic a preferential peptide conformation without any
unwanted physical and metabolite properties of peptides
(Borthwick, 2012). Borthwick (2012) observed that “the three-
dimensional structure of CDPs can overcome one of the
limitations of conventional medicinal agents, namely, the typical
planarity found in most known pharmaceutical compounds
discovered through the organic synthesis.” CDPs are easily
synthesized from readily available α-amino acids and this can
be used as core molecules around which we can construct
combinatorial libraries of compounds (Borthwick, 2012). The
advanced researches in solid-phase methodology have made
CDPs even more attractive to combinatorial drug discovery
programmes (Borthwick, 2012).
Previous literature reviews on CDPs focused on various
natural chemicals comprising the 2,5-DKP ring (Borthwick,
2012). The source, chemical synthesis, biogenesis, and various
physicochemical properties of CDPs were thoroughly studied
in 1975, but the chemistry, biology, and pharmacological
properties of many naturally occurring CDPs were reviewed
only in 1990 (Borthwick, 2012). In 1993, the chemical synthesis,
characteristics, chemical reactivity, and biological applications of
CDPs were well-reported and many other beneficial bioactivities
of simple cyclic peptides were reviewed in 1995 (Borthwick,
2012). In 2007, a short review focusing on the synthesis and
biology were published, and very recently in 2012, a report
exclusively based on properties, formation, and bioactivity of the
monocyclic 2,5-DKP was reported (Borthwick, 2012).
Cyclo(L-Leu-L-Arg) has been previously reported as a natural
compound from Streptomyces species (Tatsuta et al., 1972;
Smaoui et al., 2011) or obtained by chemical synthesis (Sasaki
et al., 1982). Till dated cyclo(D-Leu-D-Arg) is not reported
from the natural source and is reported here for the first time
fromAchromobacter sp. Antibacterial activities of this compound
against various Gram-positive and Gram-negative bacteria, as
well as antifungal activities of cyclo(L-Leu-L-Arg), have also
reported (Li et al., 2011). Smaoui et al. (2011) reported the
antifungal activity of cyclo(L-Leu-L-Arg) only against Fusarium
oxysporum by simple disc diffusion assay. In our previous
study, we reported the antifungal activity of cyclo(L-Leu-D-
Arg) isolated from Bacillus sp. N strain active against seven
medically and agriculturally important fungi (Kumar et al.,
2014c). But in the present study, the antibacterial activity of
cyclo(D-Leu-D-Arg) against some clinically relevant wound
pathogens is reported here for the first time. Chemical synthesis
of stereoisomers of cyclo(Trp-Arg) is reported earlier (Li et al.,
2012), but the isolation of cyclo(Trp-Arg) from natural source is
not reported earlier in literature and to the best knowledge this is
the first report on the isolation of cyclo(Trp-Arg) from natural
source, especially from bacteria. Here, in the present study we
reported the isolation of two enantiomers of cyclo(Trp-Arg),
i.e., cyclo(L-Trp-L-Arg) and cyclo(D-Trp-D-Arg). In the present
study cyclo(Trp-Arg) recorded excellent antibacterial activity
against bacteria associated with wound infections and the best
activity was recorded by cyclo(D-Trp-D-Arg). The antibacterial
properties of cyclo(Trp-Arg) is reported here for the first time.
The CDPs are heterocyclic molecules which can exist in
many stereoisomeric forms, and also in DD, LL, DL, and LD
forms (Kumar et al., 2014d). The stereochemistries play an
important role in the biological activity of CDPs. Antibacterial
activities of DD- and DL-CDPs [cyclo(Pro-Val)] against Vibrio
anguillarum were reported earlier, where cyclo(D-Pro-D-Val)
recorded significantly better MIC values (0.05µg/ml) than
cyclo(D-Pro-L-Val) (0.11µg/ml) (Fdhila et al., 2003; Kumar
et al., 2014d). Huberman et al. (2007) reported that out of three
CDPs enantiomers (LL, DL, and DD) tested, DD-enantiomer
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FIGURE 4 | Effects of the synergistic combination of cyclic dipeptides
and ampicillin against biofilm formation by wound associated bacterial
pathogens. Error bars indicate the standard deviations of three
measurements. Different letters in the superscript were significantly different
according to Duncan’s multiple range test (p < 0.05).
recorded best antimicrobial activity than the LL-enantiomer
especially against S. aureus and Micrococcus luteus. Based on
these results, the authors concluded that out of the three CDPs
FIGURE 5 | Effects of cyclic dipeptides on the production of (A) IL-10,
(B) IL-4, and (C) IFN-α by unstimulated and concanavalin A stimulated
human peripheral blood mononuclear cells. Error bars indicate the
standard deviations of three measurements. Different letters in the superscript
were significantly different according to Duncan’s multiple range test (p < 0.05).
enantiomers tested and DD-enantiomers recorded enhanced
bioactivity than their LL-forms. In the current investigation
cyclo(D-Trp-D-Arg) recorded significant antibacterial activity
than cyclo(L-Trp-L-Arg) and this may be due to the difference
in the chirality properties of the tryptophan and arginine that
make the change of target binding orientation of cyclo(Trp-Arg).
The higher activity of cyclo(D-Trp-D-Arg) suggests that, it can
form different spatial orientation that play a significant role in the
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FIGURE 6 | Intracellular efficacy of rifampicin in J774 murine
macrophage. (A) CDP 1, (B) CDP 2, and (C) CDP 3. Experiments were
performed three times. Error bars indicate the standard deviations of three
measurements. Different letters in the superscript were significantly different
according to Duncan’s multiple range test (p < 0.05).
enhancement of biological activity of this CDP. Stereochemistry
of the CDPs play a vital role in the improvement of bioactivity
has been reported previously on the inhibition of Bacillus sp.
chitinase by cyclo(Arg-Pro), where cyclo(L-Arg-D-Pro) is more
FIGURE 7 | Cytotoxicity of cyclic dipeptides against normal cell lines.
(A) FS normal fibroblast, (B) VERO, and (C) L231 normal lung epithelial. Error
bars indicate the standard deviations of three measurements. Different letters in
the superscript were significantly different according to Duncan’s multiple range
test (p < 0.05).
bioactive than cyclo(L-Arg-L-Pro) and this due to the existence
of D-proline in active site (Houston et al., 2004). We also
previously reported that, cyclo(D-Tyr-D-Phe) was more active
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than Cyclo(L-Tyr-L-Phe) (Kumar et al., 2014d). But linking
other DD and LL CDPs reported in the literature, no strong
connection between the enantiomers and their significant role in
the enhancement of bioactivities can be elucidated. A systematic
study on various CDPs and their corresponding enantiomers
could reveal more information on the enhanced bioactive
potential of simple CDPs (de Carvalho and Abraham, 2012).
Chronic wounds/burns are urgent global health problem
affecting human population and bacterial infection plays a very
significant role in these wounds to heal (Müller et al., 2013).
Treatment of chronic wounds with diverse bacterial flora often
involves synergistic combinations of drugs in an attempt to
enhance efficacy and this will also reduce the emergence of
antibiotic resistance (Müller et al., 2013). The synergistic effect
of two antibiotics is defined as a greater-than-2-log increase
in bactericidal activity in vitro compared with the bactericidal
activity of each antibiotic alone (Müller et al., 2013). Here,
we show conclusively that the combination of CDPs and
the antibiotic ampicillin has a significant synergistic outcome
on antibacterial activity against wound associated bacterial
pathogens. The synergistic effect of CDPs with antibiotics is
reported earlier (Kumar et al., 2013, 2014e). The synergistic
effect of natural compounds and antibiotics are a thrust area
of medicinal research with a vision for developing novel
drug combination to fight against resistant microbes. Due to
the ever increase prevalence of multi-drug resistant bacteria,
synergistic testing using various combinations of microbial
natural compounds with clinically used antibiotics could be a
powerful tool in helping to select an antimicrobial chemotherapy
more effective in low quantity, which may reduce the toxicity.
In infected chronic wound/burn, bacterial pathogens usually
survive within protective structures often termed as biofilms
(Bjarnsholt et al., 2008). Biofilms are often embedded in a
glycocalyx (mixture of extracellular polysaccharides secreted by
bacteria), that form a protective matrix adhering to the host’s
surrounding tissues around wounds/burns (Nidadavolu et al.,
2012). Moreover, biofilms play a very significant role in the
progression of many infectious diseases. Biofilms are also formed
when planktonic bacteria adhere to a host’s surface and initiate
the formation of a microcolony that exists as a community
enclosed in a protective extracellular polysaccharides secreted
by bacteria. Moreover, biofilms account for more than 90%
of wound/burn infections affecting humans and animals. In
biofilms, bacteria display differential expression of many genes
and are 1000-times more resistant to many antibiotics that are
used for treatments (Huigens et al., 2007). Therefore, biofilms are
highly resistant to host immune responses and various antibiotics
used for treatments (Donlan, 2011) and failure to eliminate
biofilmsmay eventually lead to persistent infections in the human
body (Nidadavolu et al., 2012). Here, in the present study,
CDPs and combination of CDPs with ampicillin reduces biofilm
formation for various test Gram-positive and Gram negative
bacteria. Thus, CDPs are promising candidate molecules in the
search for a broad-spectrum biofilm inhibitor.
Conclusion
Previously an enormous diversity of microbial bioactive
compounds has been reported, but only a small portion of
organisms (<1%) in nature has been explored and much more
can be expected in future. The structural variety of CDPs is
very high and there are numerous recent reports available on
new CDPs with diverse biological activities and this widens
the variety of this group of compounds. The antibacterial
activities of the CDPs especially against wound associated
human pathogenic bacteria have never reported earlier. Here,
we reported arginine based CDPs as a novel antibacterial agent
against wound associated bacteria. Moreover, this compound
recorded significant synergistic effect with ampicillin and
also in inhibiting the biofilms formed by bacteria in in vitro
conditions. Significant inhibition of biofilms was recorded by the
combination of CDPs and ampicillin. Further, studies are also
needed to determine the underlying modus operandi of CDPs on
biofilm causing bacteria. Antibacterial activity of arginine based
CDPs is an encouraging bioprobe to develop new antibacterial
therapeutics in the near future especially as topical agents against
many wound pathogens affecting human beings.
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